76 results about "Hemofiltration" patented technology

In a blood dialysis system including a source of substitution fluid (10) and a blood dialysis machine, a hemodiafiltration system having a first dialyzer (1) including a first blood compartment (4) having a first blood inlet which receives blood to be cleaned and a first blood outlet which discharges partially diafiltered blood and a first dialysate compartment (5) having a first dialysate inlet and a first dialysate outlet, means (8) for mixing the partially diafiltered blood with substitution fluid from the source to obtain a blood/substitution fluid mixture, and a second hemofilter (2) including a second blood compartment (11) having a second blood inlet which receives the blood/substitution fluid mixture and a second blood outlet which discharges filtered blood and a second permeate compartment (12) having a second permeate outlet.

A flow loop for hemodialysis, hemodiafiltration and hemofiltration for the treatment of pathological conditions such as End Stage Renal Disease (ESRD) that has a controlled compliant flow path for preparing fluids required for a hemodialysis therapy session from water. The controlled compliant flow path modifies water into any one of a solution for priming a hemodialysis system, a physiologically compatible solution for contacting blood, a physiologically compatible solution for infusion to a subject, and a solution for blood rinse back to a subject. The controlled compliant flow path has a means for selectively metering in and metering out fluid from the flow path.

Systems and methods for using a sodium chloride source and a buffer source such as sodium bicarbonate in a controlled compliant flow path to generate from water a physiologically compatible fluid having a suitable level of a sodium ion and/or a buffer for use in hemodialysis, hemodiafiltration and hemofiltration. The system has a conditioning flow path that has at least a salination valve or salination pump, and at least one container has at least one solute in excess of the solubility of that solute. At least one of the solutes is a buffer source or sodium chloride. The conditioning flow path is in fluid communication with a controlled compliant flow path. The conditioning flow path can selectively meter fluid into and out of the controlled compliant flow path.

A degassing module for removal of air and other gases during operation of a medical therapy device that delivers any one of hemodialysis, hemodiafiltration and hemofiltration. The degassing module has a flow-through first chamber that has a hydrophobic vent membrane that has an exterior and interior side forming a portion of the flow-through chamber. The hydrophobic vent membrane is positioned at a higher elevation on the flow-through chamber than a fluid outlet. Fluid flows through the flow-through chamber in a downward direction relative to the hydrophobic vent membrane. A flow-through chamber has a cross sectional area configured to provide for a downward flow velocity of the fluid to be less than the upward rise velocity of a smallest bubble to be removed from the fluid.

Systems and methods for cleaning and disinfecting a medical therapy device that delivers any one of hemodialysis, hemodiafiltration and hemofiltration. The system has a base module that has at least one segment of a controlled compliant flow path and at least one pair of jumpered ports configured on the base module. One or more components have connections connectable to the jumpered ports of the base module to provide for fluid communication between the segment of the controlled compliant flow path in the base module and a flow path defined by the one or more components. The base module is connected to the one or more components that define a flow path configurable for carrying out in part at least one function performed during any one of hemodialysis, hemodiafiltration or hemofiltration.

Method and device for monitoring the flow speed of an infusion solution, such as with hemofiltration or hemodiafiltration. The device has a tube for conducting an infusion solution from a source of infusion solution to a pump device in the form of a metering pump, such as a peristaltic pump or a ceramic pump, and on to an infusion device, such as a drip chamber. The flow speed is determined by the metering pump. The flow speed is monitored separately in that the pressure across a restriction device in the tube is measured. The restriction device can be a separately arranged restriction valve. Alternatively the restriction device is arranged by the tube having a small internal diameter of the order of 0.5 mm in size. The pressure measuring device only needs to measure the absolute pressure with respect to the atmosphere. The hydrostatic pressure due to the infusion bag being hung above the pump and the pressure meter is subtracted in a calculation device.

A method for making a polysulfone having zwitterionic functionality comprising reacting a piperazine amine functionalized polysulfone with sultone is described as are blends with other polymers. Membranes containing polysulfones having zwitterionic functionality are also provided. Membranes thus formed are used in hemodialysis, hemofiltration, and water purification.

The invention relates to extracorporeal blood circuits, and components thereof (e. g. , hollow fiber membranes, potted bundles, and blood tubing), including 0. 005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

There is provided a method of reducing blood free light chain concentration in a subject, the method comprising the step of subjecting the subject's blood to haemodialysis, haemodiafiltration or haemofiltration. There is also provided the use of a dialysis membrane which is a membrane that allows passage of molecules having a molecular weight of up to 45 kDa in presence of whole blood, and has a molecular weight exclusion limit in water of about 200 kDa in the preparation of a haemodialysis unit for conducting haemodialysis, haemodiafiltration or haemofiltration on a subject to reduce blood free light chain concentration in the patient.

The invention relates to an adsorbent used for clearing middle and macro molecule toxin in body of uremia patients and a preparation method thereof. According to the molecule size of middle and macromolecules such as beta2-MG, PTH, AGEs, Hcy and IL-6 and performance characteristics thereof, a functional adsorbent which can efficiently clear main middle and macro molecule toxins such as beta2-MG,PTH, AGEs, Hcy and IL-6 in the blood of the uremia patients is prepared by taking a mesoporous polystyrene hydrophobic resin as a carrier, which undergoes chloromethylation activation, and then performing chemical crosslinking grafting of vinylamine; and the adsorbent has large adsorption capacity, good mechanical strength, good biocompatibility and high adsorption selectivity. The adsorbent is used for treating uremia by blood perfusion, can take the advantages of blood filtering mainly for clearing micromolecular toxin, and provides a new method for treating uremia by combination of hematodialysis and blood perfusion.

Membranes for use in methods and apparatuses for hemodialysis and hemofiltration are composed of at least one polyarylethernitrile block copolymer having structural units of formula I

The invention discloses an extracorporeal circulation life supporting device used for treating and curing multiple organ failure. The extracorporeal circulation life supporting device comprises an extracorporeal circulation pipeline which is connected between a vein or artery outlet end of a patient and a vein blood inlet end of the patient; a heparin pump, a first blood pump and a second blood pump are arranged on the extracorporeal circulation pipeline in turn; the extracorporeal circulation pipeline is branched into a first branch and a second branch between the first blood pump and the second blood pump; an oxygen combiner is arranged on the first branch; the second branch extends from the second blood pump which is provided with a blood clamp, a plasma separator, an active carbon jar and a resin jar are arranged at the lower edge of the second blood pump; the plasma outputted from a side wall of the plasma separator enters into the active carbon jar and the resin jar and enters into a blood filter together with the blood cells outputted from an outlet end of the plasma separator; the blood is purified and is applied to a supporting device for curing renal failure; all the branches are converged and enter into the body of the patient from the vein end. According to the extracorporeal circulation life supporting device, one device is used for independently or jointly supporting/replacing the heart, lung, liver and renal function failure.

The invention relates to a formula of a blood filtration replacement fluid which is special for citrate anticoagulation, a preparation method and a usage thereof. With the components of sodium citrate, sodium chloride, potassium chloride, sodium lactate, citric acid and so on, the replacement fluid is mainly used for blood filtration and blood dialysis filtration of the patients with acute renal failure or high risk bleeding due to multiple organ failure etc., and can solve the problems of easy occurrence of hypernatremia and alkali poisoning in the prior citrate anticoagulation, thus facilitating the clinical usage. The replacement fluid has the advantages of strong applicability, exact efficacy and low toxicity and side effects; the preparation process is simple; the quality is stable, safe and effective; the feasibility is strong; the repeatability is high; and the replacement fluid is applicable to the large-scale production and the promotion of the clinical application, thus being the ideal blood filtration replacement fluid for blood filtration, blood dialysis filtration, continuous renal replacement therapy and so on. The demand of the blood dialysis increases along with the increasing number of the patients with the end-stage renal failure year by year, so the blood filtration replacement fluid can generate more tremendous economic and social benefits.

The invention discloses an immunochromatography test strip for detecting cystic echinococcosis and a preparation method thereof. The test strip comprises a hemofiltration membrane sample pad, a gold-marking pad, a cellulose membrane and a water absorption pad, wherein the gold-marking pad is tightly connected with the hemofiltration membrane sample pad and comprises an antibody labeling colloid gold probe of anti-echinococcus antigen advantage special antibody subtypes, the cellulose membrane is tightly connected with the gold-marking pad, the water absorption pad is tightly connected with the other end of the cellulose membrane, a detection line and a quality control line are arranged on the cellulose membrane, the detection line comprises crude antigens aiming at the cystic echinococcosis, and the quality control line comprises anti-antibodies capable of realizing special combination with the antibodies of the anti-echinococcus antigen advantage special antibody subtypes. The immunochromatography test strip of the invention has the advantages of simplicity, convenience, sensitivity, specificity and high speed, and is applicable to clinical and field use.

The general disclosure discusses a system and method for improving the efficacy of blood filtration treatments such as hemodialysis, hemofiltration, and hemodiafiltration. More particularly, the disclosure discusses a microfluidic device that includes first and second channels separated by a permeable membrane. One of the channels is configured for blood flow and includes a protein gel disruption layer. The protein gel disruption layer includes a plurality of elements at least partially extending across the blood flow channel that reduce the formation of a boundary layer or gel layer at the blood-membrane interface.

The invention belongs to the field of leukocyte filters, and particularly relates to a leukocyte and thrombocyte filtering membrane and a preparation method thereof. The filtering membrane comprises a composite substrate and a polymer applied to the composite substrate, wherein the composite substrate is prepared from polyurethane and nano-microcrystalline cellulose according to the weight ratio of 1:(0.3-2), and the polymer is prepared from polyethylene glycol and nano-hydroxyapatite according to the weight ratio of 10:(1-2). According to the filtering membrane, leukocytes and thrombocytes can be efficiently filtered while the blood filtering speed is not decreased, the highest filtering rate of the leukocytes and the highest filtering rate of the thrombocytes can reach 99.999% and 92.4% respectively, and only 15-20 min is needed for filtering 400 ml of whole blood; meanwhile, the filtering membrane has the good flexibility, meets the requirement that moderate deformation is needed when the filtering membrane is packaged and can effectively solve the problem that the polymer is prone to be washed out in the subsequent washing process.

The invention relates to a preparation method of blended kynoar polyvinylidene fluoride hollow fabulous membrane for blood filtration, comprising steps of (1) taking kynoar polyvinylidene fluoride, phenolphthalein aryl ether sulfone, neutral polymeric adsorbent powder, pore former and solvent, and stirring; (2) filtering and de-foaming spinning dope, extruding from a spinneret composed of two cocentric tubes; after 20 to 800mm dry spinning process, solidifying, primarily generating filaments, after bi-directionally drawing and retracting for over four times, water washing and treating with hole retaining agent, winding at speed of 10 to 60m/min, thus obtaining the hollow fabulous membrane. The method is simple and is applied to industrial production. The obtained hollow fabulous membrane has advantages of low shrinkage and high flux, is applied to directly clear endogenous and exogenous toxicant in human body, has good clearing effect to toxicant having middle and low molecular mass in blood and is applied to blood filtration.

The present invention relates to a method and system for using a hemofilter to treat IMRD, hepatic failure, exogenous intoxication and other conditions associated with toxins in a patient's blood. One treatment includes the use of a very large pore hemofilter to remove target complex molecules and/or target molecules from a patient's blood and to infuse a replacement fluid into the patient's blood to maintain a prescribed albumin concentration in the patient's blood.